VA’s Vista program achieves integration with GE CIS
VA’s Vista program achieves integration with GE CISThe U.S. Department of Veterans Affairs’ (VA) Vista Interface Program and GE Marquette Medical Systems have developed interfaces that enable the Vista computerized patient record and
VAs Vista program achieves integration with GE CIS
The U.S. Department of Veterans Affairs (VA) Vista Interface Program and GE Marquette Medical Systems have developed interfaces that enable the Vista computerized patient record and information system to share and exchange data with GEs QS Critical Care Clinical Information System. The interfaced systems also house a clinical data repository. The program is attempting to gain Class 1 status for this process, meaning that the software would become public property available to 150 VA medical centers and would be maintained by the VAs national information technology group. GE is the sole corporate supporter of this program, which is open to all vendors.
- Search Again
- Return To HNN Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
